The present disclosure is related to apparatus and methods to obtain vascular access and more particularly to a kit, apparatus contained in the kit and associated methods which may be used to provide access to bone, bone marrow and other portions of a patient's vascular system using the apparatus.
Every year, millions of patients are treated for life threatening emergencies in the United States. Such emergencies include shock, trauma, cardiac arrest, drug overdoses, diabetic ketoacidosis, arrhythmias, burns, and status epilepticus just to name a few. For example, according to the American Heart Association, more than 1,500,000 patients suffer from heart attacks (myocardial infarctions) every year, with over 500,000 of them dying from its devastating complications. In addition, many wounded soldiers die unnecessarily because intravenous (IV) access cannot be achieved in a timely manner. Many soldiers die within an hour of injury, usually from severe bleeding and/or shock.
An essential element for treating all such emergencies may be the rapid establishment of an IV line in order to administer drugs and fluids directly into the circulatory system. Whether in the ambulance by paramedics, in the emergency room by emergency specialists or on the battlefield by an Army medic, a common goal is to start an IV as soon as possible to administer life saving drugs and fluids. To a large degree, the ability to successfully treat such critical emergencies may be dependent on the skill and luck of the operator in accomplishing vascular access. While it may be relatively easy to start an IV on some patients, doctors, nurses and paramedics often experience difficulty establishing IV access in approximately twenty (20%) percent of patients. The success rate on the battlefield is often much lower where Army medics may only be about twenty-nine (29%) percent successful in starting an IV line during emergency conditions in the field. These patients are probed repeatedly with sharp needles in as attempt to solve this problem and may require an invasive procedure to finally establish an intravenous route.
In the case of patients with chronic disease or the elderly, the availability of easily accessible veins may be depleted. Other patients may have no available IV sites due to anatomical scarcity of peripheral veins, obesity, extreme dehydration or previous IV drug use. For these patients, finding a suitable site for administering life saving drugs may become a difficult and frustrating task. It is generally well known that patients with life threatening emergencies have died because access to the patient's, vascular system with life saving IV therapy was delayed or simply not possible.
An accepted alternative route to give IV medications and fluids is through bone marrow by providing intraosseous (IO) access. Drugs and other fluids may enter a patient's vascular system just as rapidly via the intraosseous route as when given intravenously. Bone and associated bone marrow may be considered a large, non-collapsible vein. The IO route has been used for alternative emergency access in pediatric patients, whose bones are soft enough to permit manual insertion of IO needles.
The present disclosure relates to kits, apparatus contained in such kits and associated procedures to obtain access to a patient's vascular system. For some embodiments such kits may include intravenous (IV) access devices and intraosseous (IO) access devices. Such kits may be used in both emergency situations or more routine procedures associated with treating chronic conditions. The present disclosure may provide apparatus and methods to establish vascular access during treatment of a patient at a wide variety of locations and facilities including, but not limited to, accident sites, emergency rooms, battlefields, emergency medical services (EMS) facilities, oncology treatment centers, chronic disease treatment facilities and veterinary applications.
Technical benefits of some embodiments may include providing portable kits with devices and components for rapid penetration of bone and bone marrow to provide access to a patient's vascular system.
Technical benefits of some embodiments may include devices and components for rapid penetration of bone and associated bone marrow. Such devices and components may be placed in a kit for use in accessing a patient's vascular system.
Technical benefits or some embodiments may include obtaining fast, inexpensive access to a patient's vascular system with minimal risk. Apparatus and methods incorporating teachings of the present disclosure may be used to provide IO and IV access so that drugs and/or fluids can be injected into associated bone marrow.
A more complete and thorough understanding of various embodiments and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, in which like reference numbers indicate like features, and wherein:
Preferred embodiments and associated features and benefits may be understood by reference to
Vascular system access is essential for the treatment of many serious diseases and conditions and almost every serious emergency. Yet, many patients experience extreme difficulty obtaining timely treatment because of the inability to obtain or maintain venous access. The intraosseous (IO) space provides a direct conduit to systemic circulation and, therefore, is an attractive route to administer intravenous (IV) drugs and fluids. Rapid IO access offers great promise for almost any serious emergency than requires IV access to administer life saving drugs or fluids when traditional IV access is difficult or impossible.
IO access may be used as a “bridge” (temporary fluid and drug therapy) during emergency conditions until conventional IV sites can be found and utilized. This often occurs because fluids and/or medication provided via an IO access may stabilize a patient and expand veins and other portions of a patient's vascular system. Kits with IO devices and associated procedures incorporating teachings of the present disclosure may become the standard of care for administering medications and fluids in situations when IV access is difficult or not possible.
IO access generally provides rapid and reliable vascular access to administer life saying drugs or fluids, when traditional IV access is difficult or impossible. Such emergencies include shock, trauma, cardiac arrest, drug overdoses, diabetic coma, burns, dehydration, seizures, allergic reactions, and arrhythmias. There are more than 100 million visits to emergency rooms annually. Statistics show that vascular access may be difficult or impossible in 4 million patients annually.
Intraosseous access may be used as a “routine” procedure with chronic conditions which substantially reduce or eliminate the availability of conventional IV sites. Examples of such chronic conditions may include, but are not limited to, dialysis patients, seriously ill patients in intensive care units and epilepsy patients. Kits and intraosseous devices incorporating teachings of the present disclosure may be quickly and safely used to provide IO access to a patient's vascular system in difficult cases such as status epilepticus to give medical personnel an opportunity to administer crucial medications and/or fluids. Further examples of such acute and chronic conditions are listed near the end of this written description.
The term “driver” may be used in this application to include any type of powered driver or manual driver satisfactory for inserting an intraosseous device such as a penetrator assembly or IO needle into selected portions of a patient's vascular system. Various techniques may be satisfactorily used to releasably engage or attach an IO device and/or penetrator assembly with manual drivers and powered drivers. Various features and benefits of the present disclosure may be described with respect to kit having a driver to insert an intraosseous (IO) device into bone marrow of a patient at a selected insertion site. However, a kit with devices and components incorporating teachings of the present disclosure may be satisfactorily used to access various portions of a patient's vascular system. The present disclosure is not limited to IO devices and procedures.
The term “kit” may be used in this application to describe a wide variety of bags, containers, carrying cases and other portable enclosures which may be used to carry and store intraosseous devices and/or intravenous devices along with related components and accessories. Such kits and their contents along with applicable procedures may be used to provide access to a patient's vascular system in accordance with teachings of the present disclosure.
The present disclosure includes a wide variety of kits, devices and associated components which may be used to obtain vascular access to a patient. In some embodiments, such kits may include apparatus operable to access a patient's bone marrow using a driver, an intraosseous needle and one or more connectors to communicate fluids with the patient's bone marrow. Such kits may also include apparatus which allows monitoring a patient.
Kits incorporating teachings of the present disclosure may be rigid, semi-rigid or soft-sided. Such kits may provide a convenient way to carry various components and devices operable to achieve vascular access in an organized and systematic fashion. Such kits may present EMS first responders and other medical personnel with a well organized collection of components and devices to achieve vascular access by placement of peripheral intravenous (IV) catheters and/or intraosseous (IO) catheters. For some embodiments, a kit incorporating teachings of the present disclosure may be combination an IV kit, an IO kit and/or a unit dose kit in one convenient bag. Examples of various types of devices and components which may be carried in a kit in accordance with teachings of the present disclosure are shown in
Securing devices incorporating teachings of the present disclosure may be provided in kits to allow easy removal and replacement of associated drivers. Such securing devices may include a wide variety of cradles and other types of holders with relatively rugged snap-in features to prevent undesired release of a driver from an associated securing device. Securing devices may be formed from plastic and/or glass composite materials to provide durability for repeated replacement and use of an associated driver. Such securing devices may releasably hold an associated driver in place within a kit so that the driver does not interfere with other devices and components disposed in the kit. A securing device may be positioned in a kit to clearly present an associated driver to a user during consideration of alternate vascular access routes.
Securing devices incorporating teachings of the present disclosure may make it easy for a user to extract an associated driver from a kit using only one hand. Other components such as penetrator assemblies and IO needles may be conveniently located in the kit to further minimize time and manipulations required for a user to attach an IO needle and insert the IO needle at a desired site in a patient. Such securing devices may also provide an easy site to return the driver to the kit after use. The associated driver may snap into place to securely protect the driver against accidental deployment until required for use in providing another IO access.
Kits incorporating teachings of the present disclosure may be used in locations where ruggedness and durability are of paramount importance. Such kits may be washable, water proof, temperature resistant, and/or crush proof. Such kits may have a wide variety of different shapes and colors. Kits incorporating teachings of the present disclosure may be any size as required to contain selected IO devices and IV devices which may be used to obtain vascular access. In some embodiment kits may be approximately ten inches in length by six to eight inches in width.
For some applications kits incorporating teachings of the present disclosure may be designed for use in military applications. Such kit may be as compact as feasible with components disposed in one or more compartments as necessary for an efficient use of space. Such kits may also include a manual intraosseous driver and related intraosseous components to access a patient's vascular system. Such kits may include intraosseous catheters, intravenous catheters, containers with sterile normal saline, tourniquets and IO/IV securing devices. Various components may be configured for particular branches of the military, e.g., Army, Navy, Air Force, Coast Guard and Special Forces.
Another benefit of the present disclosure may include forming a kit with one or more dividers having components and devices arranged in order on page one and page two corresponding with steps of a procedure such as treating a patient with an emergency condition or treating a patient for a chronic condition. The pages in a kit may be arranged to accommodate a wide variety of procedures. For example, if a kit will be used in an oncology related application or for treatment of other chronic conditions, the “pages” in the kit may be arranged based on the steps required to provide access to a patient's vascular system and to carry out a planned treatment.
Various techniques and procedures may be used to position and securely engage a supporting structure for an IO device at an insertion site. For some applications, various types of straps may be used. See
Some features and benefits of the present disclosure may be described with respect to kit 20 (See
For some applications kits 20, 20a and/or 120 may he semi-rigid or soft sided. Kits 20, 20a and 120 may be formed from a wide variety of materials including, but not limited to, nylon cordura type materials, various types of polymeric and plastic materials. For some applications kits 20, 20a and/or 120 may be formed from relatively soft materials such as canvas, polyesters and similar materials. For other applications kits incorporating teachings of the present disclosure may be relatively rigid and formed from materials such as lightweight aluminum alloys and similar hard materials.
For embodiments such as shown in
For some applications, kits 20 or 20a may be generally described as a two part molded case formed at least in part by compression molding ethylene vinyl acetate (EVA) foam. EVA may be generally described as a polymeric material with some of the characteristics of elastomeric materials and some characteristics of thermal plastic materials. However kits incorporating teachings of the present disclosure may be formed from a wide variety of polymeric materials, elastomeric materials and/or thermoplastic materials.
Kits 20 and/or 20a may have a nominal wall thickness of approximately 0.19 inches. Exterior surfaces of kits 20 and/or 20a may be covered by a durable layer of heavy dinear polyester or other suitable material. Interior portions of kits 20 and/or 20a may be formed in part by relatively smooth layers of urethane or relatively smooth layers of polyvinyl chloride (PVC). Such materials allow interior portions of kits 20 and/or 20a to be more easily cleaned, particularly after use during an emergency at a field location.
Kits 20 and/or 20a may have two segments or enclosures 22 and 24 with generally hollow, rectangular configurations and compatible dimensions. As a result first segment 22 and second segment 24 may be releasably engaged with each other to form an enclosure having desired dimensions and configurations to efficiently carry IO and IV devices and components associated with kits 20 and 20a. For some applications, first segment 22 and second segment 24 may have approximately the same dimensions and configurations such that each segment 22 and 24 may form approximately one-half of the resulting kit. For applications such as shown in
For purposes of describing various features of the present disclosure, first segment 22 may be described as having generally rectangular bottom layer or base 30 with respective pairs of walls 34 and 36 extending therefrom. Bass 30 may also include first surface or interior surface 31 (See
Second segment 24 may be defined in part by top layer or cover 40. Sometimes top layer 40 may also be referred to as a lid. Top layer 40 may include first surface or interior surface 41 (See
For some applications, a pair of zippers 28 and 29 may be used to releasably engage second segment 24 with first segment 22 when associated kits 20 or 20a is in their respective first, closed position. (See
First segment 22 and second segment 24 may be hinged with each other along one side of respective kits 20 and 20a. Fabric type hinge 58 or other suitable low cost, reliable hinge mechanism may be used to allow movement of second segment 24 relative to first segment 22 to open and close the associated kit 20 or 20a. Handle 26 may be attached with exterior portion of kits 20 and 20a opposite from the hinge 58 located on interiors of kits 20 and 20a. Handle 26 may be formed from lightweight, durable web type material or any other suitable material.
Zippers 28 and 29 may be moved around the three edges of contact between first enclosure 22 and second enclosure 24 to engage and disengage adjacent portions of enclosures 22 and 24. Zippers 28 and 29 and associated zipper mechanisms may be formed from durable, rustproof material and extend along three edges of contact between first enclosure 22 and second enclosure 24.
After kits 20 and/or 20a have been used at a field location or at a medical facility, the used kit may be returned to a central location for cleaning and replacement of any missing components or devices. For some applications breakable seal 23 (See
One or more panels or dividers may be disposed within kits incorporating teachings of the present disclosure. The dividers may also be referred to as “boards.” For embodiments represented by kits 20 and 20a one edge of each divider 50 may be engaged with associated hinge 58 to allow rotating movement of each divider 50 relative to hinge 58 when associated kit 20 or 20a is in its first, open position.
Dividers 50 may be formed from polyvinyl chloride (PVC) or other suitable materials. Each divider 50 may have a generally rectangular configuration with dimensions compatible with nesting each divider within segments 22 and 24 when associated kit 20 or 20a is in its first, closed position. For some applications dividers 50 may be about 0.050 to 0.060 inches thick. The width and other characteristics of hinge 58 may also be selected to accommodate nesting of each divider 50 within segments 22 and 24 when associated kit 20 or 20a is in its first, closed position.
Each divider 50 may also include first surface 51 and a second surface 52. Surfaces 51 and 52 may sometimes be referred to as “pages.” For embodiments such as shown in
For example, “page one” or first surface 51 of divider 50 may present EMS personnel with devices, components and instructions used to select and clean a site for vascular access. Such components and devices may include containers 62 with cleaning fluids, alcohol wipes or other prep materials, flashlight 64 and a tourniquet (not expressly shown). Written instructions for selecting an insertion site and/or locating a vein may be provided in pockets 56 on page one.
“Page Two” or second surface 52 of divider 50 may include devices and components that allow EMS personnel to access a patient's vascular system via a peripheral vein or an intraosseous route. Such components may include intravenous catheters, intraosseous needles and other components that may be used to access a patient's vascular system. As shown in
For some applications, interior surface 41 of cover 40 may also function as page three with additional devices, components and instructions attached thereto. For example, when kits 20 and/or 21a are used in an emergency environment to provide IO access to a patient, interior surface 41 or page three may include devices and components used to secure and intraosseous device and/or an IV device at the insertion site and to further prepare the patient for movement to an EMS treatment facility. Components and devices such as tape, dressing materials, an arm-board or splint and other components operable to secure a catheter or an intraosseous line may be provided on page three. Various types of straps and supporting structures for IO devices may be releasably attached to page three or interior surface 41. See some examples in
Outside pocket 60 formed from mesh type material may be attached to exterior surface 42 of cover 40. Outside pocket 60 may hold printed reference materials such as quick reference cards. For some applications elastic cords (not expressly shown) may also be provided on exterior portion of kits 20 and 20a to hold such materials.
Velcro or elastic strips or loops or any other fastening device may be used to position components on dividers 50. In lieu of dividers 50, IO and IV devices and related components may be configured in some other arrangement or organizing mechanism such as compartments or smaller containers carried in a kit.
A device for accessing an intraosseous space such as a powered driver (See
Powered driver 200 may include housing 202 with various types of motors and/or gear assemblies disposed therein (not expressly shown). A rotatable shaft (not expressly shown) may be disposed within housing 202 and connected with a gear assembly. Various types of fittings and/or connectors may be disposed proximate one end of the rotatable shaft extending from end 204 of housing 202. For some applications a pin type fitting or connector such as drive shaft 218 may be used. A matching box type fitting or connector receptacle may be provided on an intraosseous device such that power driver 200 may be releasably engaged with the intraosseous device. For some applications, drive shaft 216 may have a pentagonal shaped cross section with tapered surfaces formed on the exterior thereof. Fittings and/or connections with various dimensions and configurations may be satisfactorily used to releasably engage an intraosseous device with a powered driver.
Container 230 as shown in
Handle 206 may include a battery (not expressly shown) or other power source. Handle 206 may also include trigger assembly 208 for use in activating powered driver 200. Examples of powered drivers are shown in pending patent applications Ser. No. 10/449,503 filed May 30, 2003 entitled Apparatus and Method to Provide Emergency Recess To Bone Marrow, Ser. No. 10/449,476 filed May 30, 2003 entitled Apparatus and Method to Access Bone Marrow and Ser. No. 11/042,912 filed Jan. 25, 2005 entitled Manual Interosseous Device.
Various types of intraosseous devices, intraosseous needles and/or penetrator assemblies may be carried in a kit incorporating teachings of the present disclosure. See for example
For some applications a securing device designed to accommodate one or more specific types of drivers may be disposed within first segment 22. For other applications more generic types of holders or cradles may be placed within first segment 22. For embodiments such as shown in
Length 82 and width 84 of cradle 80 may be selected to be compatible with interior dimensions of first enclosure 22 and similar dimensions associated with a driver that will be releasably engaged with cradle 80. For some applications first end 86 and second end 88 may have generally rounded configurations. Notch 90 may be formed in first end 86 to accommodate drive shaft 216 extending from end 204 of power driver 200.
First longitudinal edge 91 and second longitudinal edge 92 may be spaced from each other and extend generally parallel with each other between first end 86 add second end 88. For some applications, ends 86, 88 and longitudinal edges 91, 92 may fit flush with interior surface 31 of bottom layer 30. Maintaining close contact between interior surface 31 and adjacent portions of cradle 80 may substantially reduce or minimize problems associated with cleaning an associated kit after use, particularly after used during an emergency at a field location.
Various types of holders, clamps and/or quick release mechanisms may be provided on a cradle incorporating teachings of the present disclosure. For embodiments represented by cradle 80 a pair of arms 94 and 96 may project from respective longitudinal edges 91 and 92 . Arms 94 and 96 may be relatively strong with sufficient flexibility to allow inserting and removing portions driver 200 from engagement with cradle 80. The height of arms 94 and 96 relative to longitudinal edges 91 and 92 may be based at least in part on the height or depth of first enclosure 22 and corresponding dimensions of driver 200. Support surface 98 may be disposed between arms 94 and 96 in an elevated position relative to longitudinal edges 91 and 92. The location of support surface 98 may be selected to accommodate corresponding dimensions of driver 200 and particularly handle 206.
The spacing or gap formed between first arm 94 and second arm 96 may be selected to accommodate the width of handle 206 of driver 200. Respective ribs 100 may be formed approximate the end of each arm 94 and 96 opposite from longitudinal edges 91 and 92. Ribs 100 preferably extend inwardly relative to associated arm 94 and 96. The dimensions of arms 94 and 96, the gap formed therebetween, and associated ribs 100 may be selected to be compatible with forming a snug but releasable snap type fit with adjacent portions of handle 206 of driver 200.
For some applications first wall 104 and second wall 106 may be disposed between first end 86 and supporting surface 98 such as shown in
One or more holes 108 may be formed in cradle 80 approximate first end 86 and second end 88. Holes 108 may be sized to receive various types of fasteners such as rivals and/or screws (not expressly showed). Such fasteners may be used to secure cradle 80 at a desired location within first enclosure 22.
Materials used to form cradle 80 may be relatively low cost but must also have sufficient durability for repeated insertion and removal of an associated driver. For some applications arms 94 and 96 may be designed to allow insertion and removal of an associated driver at lease five hundred times. Arms 94 and 96 may also have sufficient stiffness and strength to allow associated driver 200 to snap into place. The stiffness of arms 94 and 96 may be selected such that driver 200 will not be inadvertently released from cradle 80 if kit 20 or 20a should be dropped or otherwise mishandled.
For embodiments such as shown in
Various types of indicator lights may be used. For some applications light 74 may be yellow to indicate that a battery (not expressly shown) in power driver 200 needs to be recharged. Light 76 may be green to indicate that the charging is not required or that charging of associated powered driver 200 has been satisfactorily completed. For some applications, kit 20a will preferably be in its first, open position during charging Of powered driver 200.
Prehospital and combat situations are often ideally suited to use “unit dose” containers of various types of medications. Emergency medical personnel often need only a one-time dose of medication, such as an antidote for poison or epinephrine to stabilize the patient. Unit dose ampules are widely used by paramedics to give a predetermined amount of medication for a particular indication. A limited number of drugs may satisfactorily fill such needs.
Kit 120 as shown in
Kit 120 may include base portion 130 and cover 140. Zipper 122 or other types of closures may be satisfactorily used to releasably engage cover 140 with base portion 130. For some applications a pair of zippers and a breakable seal such as shown in
For embodiments such as shown in
Base 130 may be formed from a relatively thick layer of material satisfactory for use. A plurality of holes may be formed in interior surface 132 of base 130 satisfactory to accommodate releasably storing each ampule 123-127 in a respective hole. The exterior configurations of base 130 may also be defined in part by walls and rounded corners which are preferably compatible with the walls and rounded corners associated with cover 140.
Base portion 130 as shown in
The ability to satisfactorily insert an IO device such as an IO needle at a desired insertion site may be problematic when a patient is moving or has the potential to move. Inserting an IO device in the wrong place may expose a patient to potential harm. Patient movement may be of special concern for patients suffering from status epilepticus or violent patients (drug overdoses or mental status changes) that need to be controlled for their safety and treatment. Epileptic patients may shake violently for prolonged periods which makes starting a conventional IV nearly impossible. Likewise, it may be difficult to accurately place an IO device at a desired insertion site in these patients. Although target areas for successful IO placement such as a patient's tibia and humerus are often larger than target areas for placement of an IV device, problems with inserting an IO device at a desired insertion site may be minimized by using stabilization devices and supporting structures incorporating teachings of the present disclosure. Such devices and supporting structures may be easy to apply, even in difficult field environments.
First end or tip 161 of IO needle 160 may be designed to drill or cut through bone 152 and penetrate associated bone marrow 154. Tip 161 may be open to allow communication of fluids with bone marrow 154. Also, one or more side ports 164 may be formed in IO needle 160 to allow communication of fluids therethrough. Second end 162 of IO needle 160 may have various types of connections including, but not limited to, a conventional Luer lock connection (not expressly shown) associated with supplying IV fluids and medications to a patient.
Strap 170 and supporting structure 180 such as shown in
Strap 170 may include first end 171 and second end 172 sized to be inserted through holes 181 and 182 of supporting structure 180. Strap 170 and supporting structure 180 cooperate with each other to prevent accidental removal or withdrawal of IO needle 160 from an insertion site. Strap 170 and supporting structure 180 also cooperate with each other to prevent excessive movement or rocking of IO needle 160 relative to the insertion site.
Supporting structure 180 may include relatively short, hollow cylinder 184 with a pair of flanges or wings 186 extending therefrom. Holes 181 and 182 may respectively be formed in each wing or flange 186. Wings 186 may be formed from relatively flexible material which will conform with adjacent portions of a patient's skin, soft tissue and bone. Hollow cylinder 184 may be formed from relatively rigid material to prevent undesired movement of associated IO needle 160. Interior dimensions of hollow cylinder 184 may correspond approximately with the exterior dimensions of IO needle 160 to provide a relatively snug fit therebetween.
For embodiments such as shown in
Supporting structure 180a may be placed at an IO insertion site. Buckle 174a at first end 171a of strap 170a may be releasably engaged with corresponding projection 181a. Strap 170a may then be extended around patient's leg or other bone to allow engaging buckle 174a at second end 172a with associated projection 182a. For such applications, strap 170a may be formed from elastomeric material.
For some applications supporting structure 180 may be placed at an insertion site prior to installing IO device 160. IO device 160 may then be inserted through the longitudinal bore of supporting structure 180. For other applications an IO device with exterior dimensions and exterior configuration of the IO device may be compatible with interior dimensions 188 of supporting structure 180 may first be installed at a desired insertion site. Supporting structure 180 may then be fitted over the installed IO device (not expressly shown) by placing the IO device through the longitudinal bore of supporting structure 180. Strap 170a may then be engaged with respective projections 181 and 182.
Seal assembly 195 may be used to isolate transducer wire 196 so that infusions of fluids may proceed while, at the same time, measuring intravenous pressure at tip 161. Measurements from sensor 192 may be analyzed by a computer (not expressly shown) to manage changes in a patient's condition by initiating pre-set increases in infusion pressure, controlling the rate of infusion or stopping infusion all together and alarming the patient and/or medical personnel if pressure limits are exceeded.
Supporting structure or guide 180c may be formed from various polymeric and/or thermoplastic materials having desired rigidity and strength to direct insertion of an intraosseous device at a desired insertion site. Supporting structure 180c may also be formed from various types of elastomeric and/or nonelastomeric materials satisfactory for use in forming a guide or supporting structure to direct insertion of an intraosseous device at a desired insertion site.
For some applications strap 170c may include one or more strips of hook and loop type material 198 (sometimes referred to as Velcro® strips) disposed proximate first end 171c and second end 172c of strap 170c. The configuration, size and dimensions of Velcro® strips 198 may be modified to allow strap 170c to releasably attach supporting structure 180c with a leg or other portions of a patient's body having various dimensions. For some applications supporting structure 180c may include target 199 disposed within recess 194 for use by an operator to more precisely direct insertion of an associated IO device at a desired insertion site.
Manual driver 200a may include handle 212 with drive shaft 216 extending therefrom. Manual driver 200a may also include an optional ratchet mechanism (not expressly shown). Handle 212 may be formed in a variety of shapes, such as with finger grips 214. Handle 212 may be formed from materials satisfactory for multiple uses or may be formed from materials satisfactory for one time or disposable use. Handle 212 may have an ergonomically designed shape suitable for grasping with a hand and/or fingers during manual insertion of an IO device into bone and associated bone marrow.
For some applications penetrator assembly 240 may include connecter 250 with inner penetrator or trocar 260 extending therefrom and hub 270 with outer penetrator or cannula 280 extending therefrom. Connector 250 and hub 270 may be releasably engaged with each other using Luer type fittings, threaded connections or other suitable fittings formed on second end 252 of connector 250 and first end 271 of huh 270. Outer penetrator 280 may extend from second end 272 of hub 270.
For some applications outer penetrator or cannula 280 may be described as a generally elongated tube sized to receive inner penetrator or stylet 260 therein. Portions of inner penetrator 260 may be disposed within a longitudinal passageway 276 extending through outer penetrator 280. The outside diameter of inner penetrator 260 and the inside diameter of longitudinal passageway 276 may be selected so that inner penetrator 260 may be slidably disposed within outer penetrator 280. Outer penetrator 280 may be formed from stainless steel, titanium or other materials of suitable strength and durability to penetrate bone and magnetic characteristics to allow releasable engagement with disc 254.
Tip 281 of outer penetrator 280 and/or tip 261 of inner penetrator 260 may be operable to penetrate bone and associated bone marrow. The configuration of tips 261 and/or 281 may be selected to penetrate a bone or other body cavities with minimal trauma. First end or tip 261 of inner penetrator 260 may be trapezoid shaped and may include one or more cutting surfaces. In one embodiment outer penetrator 280 and inner penetrator 260 may be ground together as one unit during an associated manufacturing process. Inner penetrator 260 may also include a longitudinal groove (not expressly shown) that runs along the side of inner penetrator 260 to allow bone chips and/or tissues to exit an insertion site as penetrator assembly 240 is drilled deeper into an associated bone.
Hub 270 may be used to stabilize penetrator assembly 240 during insertion of outer penetrator 280 into a patient's skin, soft tissue and adjacent bone at a selected insertion site. First end 271 of huh 270 may be operable for releasable engagement or attachment with associated connector 250. Second end 272 of hub 270 may have a size and configuration compatible with an associated insertion site. The combination of hub 270 with outer penetrator 280 may sometimes be referred to as a penetrator set or an intraosseous needle.
For some applications connector 250 may be described as a generally cylindrical tube defined in part by first end 251 and second end 252. The exterior of connector 250 may include an enlarged tapered portion adjacent to end 251. A plurality of longitudinal ridges 256 may be formed on the exterior of connector 250 to allow an operator to grasp associated penetrator assembly 240 during attachment with drive shaft 216. Longitudinal ridges 256 also allow connector 250 to be grasped for disengagement from hub 270 after outer penetrator 280 has been inserted into a bone and associated bone marrow. Disc 254 may be disposed within receptacle or opening 256 for use in releasably attaching connector 250 with drive shaft 216.
For some applications disc 254 may be a magnet. For such applications drive shaft 216 may be formed from various types of metallic materials with magnetic characteristics compatible with releasable engagement of drive shaft 216 with the magnetic disc 254 disposed in penetrator assembly 240. For other applications a magnet (not expressly shown) may be formed on the end of drive shaft 216. For such applications disc 254 may be formed from various types of metallic material with characteristics compatible with releasably engaging penetrator assembly 240 with the magnet formed on the end of drive shaft 216.
First end 271 may have a generally cylindrical pin type configuration compatible with releasably engaging hub 270 with second end or box end 252 of connector 250. Second end 252 of connector 250 may include opening 258 sized to receive first end 271 of hub 270 therein. Threads 259 may be formed in opening 258 adjacent to second end 252 of connector 250. Threads 273 may be formed proximate end 271 of hub 270. Threads 259 and 273 may be used to releasably attach connector 250 with first end 271 of hub 270.
For some applications end 272 of hub 270 may have the general configuration of flange. Angular slot or groove 274 sized to receive one end of protective cover or needle cap 290 may be formed in end 272. Slot or groove 274 may be used to releasable engage cover 290 with penetrator assembly 240. For some applications cover 290 may be described as a generally hollow lube having rounded end 292. Cover 290 may be disposed within associated slot 24 to protect portions of outer penetrator 280 and inner penetrator 260 prior to attachment with a driver. Cover 290 may include a plurality of longitudinal ridges 294 formed on the exterior thereof. Longitudinal ridges 294 cooperate with each other to allow installing and removing cover or needle cap 290 without contaminating portions of an associated penetrator. Cover 290 may be formed from various plastics and/or metals.
Examples of acute and chronic conditions which may be treated using kits, intraosseous devices, intravenous devices and procedures incorporating teachings of the present disclosure include, but are not limited to, the following:
More than 35,000 Advanced Cardiac Life Support (ACLS) ambulances are in service in the U.S. Each is equipped with emergency drugs and devices. Most are required to carry intraosseous needles and paramedics are trained in their use for pediatric emergencies. Kits incorporating teachings of the present disclosure may be used so administer medications and treats before permanent damage to a patient occurs.
More than 4,000 emergency rooms in the U.S. are required to treat life-threatening emergencies like shock trauma and cardiac arrest. ERs are stocked with the latest devices and equipment to help patients receive state-of-the-art treatment. However, there is no more exasperating situation for the physician or potentially catastrophic condition for the critical patient, than the inability to establish intravenous access. Kits with IO devices incorporating teachings of the present disclosure may provide a simple and straightforward solution for extremely difficult clinical problems.
Hospitals are required to provide crash carts on every patient ward. It is estimates that 6,000 U.S. hospitals stock more than 60,000 crash carts. These crash carts are stocked with defibrillators, IV access devices, including central venous catheters, IV fluids and drugs for common emergencies. Nurses and other healthcare workers using those crash carts are often inexperienced in such emergencies and have difficulty establishing IV access. A kit with IO devices incorporating teachings of the present disclosure may provide the long sought IV alternative for difficult patients.
Automatic injectors are widely used in the military. During Desert Storm, combat soldiers carried an atropine auto-injector for nerve gas poisoning. Current auto-injectors are limited to intramuscular injections. The Kits with IO devices may vastly expand the scope of treatment to include intravenous drugs, without having to be skilled in the technique of intravenous insertion.
Most acute care hospitals in the U.S. operate Intensive Care Units (ICUs) for seriously ill patients. Establishing and maintaining venous access in these patients is often a challenge. IO access may be a welcome procedure for administration of drugs and fluids to these critical patients.
Ten percent of the population experience a major seizure in their lifetime and more than 2,500,000 people in the United States have epilepsy. Grand mal seizures represent one of the most dramatic events in medicine. During the seizure, which usually lasts 60 to 90 seconds, patients typically fall to the ground, become rigid with trunk and extremities extended, and shake violently. The most dreaded progression of seizures is status epilepticus, a condition defined as a continuous seizure lasting more than 30 minutes or two or more seizures that occur without full conscious recovery between attacks. Convulsive status epilepticus requires urgent, immediate treatment. Patients are at risk for serious injury, hypoxemia, circulatory collapse, permanent brain damage and death. The overall mortality of convulsive status epilepticus is up to 35 percent.
Intravenous access with a large bore needle/catheter must be established to administer anticonvulsant medications. These include a benzodiazepine followed by phenytoin and/or phenobarbitol for immediate seizure control and prevention of further seizures. There are no satisfactory oral, rectal, or intramuscular medications that will control status epilepticus.
The problem facing clinicians and paramedics treating patients with status epilepticus is the difficulty establishing venous access. Without adequate venous lines none of the effective anticonvulsants can be given. During seizures the violent shaking makes accessing a satisfactory vein difficult. Often after the line is established, further shaking dislodges the IV or causes it to infiltrate.
Further, caregivers are at great risk of puncturing themselves with a needle when attempting to establish venous access in a patient during a seizure. Through no fault of their own, seizing patients, by jerking and thrashing around, turn the safest procedure into a terrifying venture. Doctors, nurses, and paramedics work in mortal fear of contracting AIDS and hepatitis through an inadvertent puncture with a contaminated needle.
In an attempt to solve the venous access problem, emergency physicians and intensivists have turned to establishing a central line (intravenous catheter placed in a large central vein such as the subclavian or femoral vein). However, with this method, even under ideal conditions, there is an increased incidence of serious side effects such as pneumothorax, hemothorax, inadvertent puncture of a major artery, infection, venous thrombosis, and embolus. In the case of a patient with status epilepticus, this method becomes increasingly difficult and dangerous for all of the above-mentioned reasons. Therefore, most doctors are reluctant to even attempt a central line until seizures have ceased.
Dialysis patients who often come to the emergency room in life threatening situations such as pulmonary edema (water on the lungs) or high potassium, leading to cardiac arrest. These patients typically have troublesome or non-existent veins. The IO access may give these patients hope for a better quality of live and decrease their mortality.
Drug overdose victims, often comatose, generally require immediate IV access to give antidotes and life saving medications such as Narcan. These patients usually have difficult venous access due to long term abuse of their veins. IO access may give these patients an alternate route for delivery of medications and fluids while improving the safety of the healthcare workers.
Trauma victims and attempted suicide patients, often in shock due to blood loss, may also require swift replacement of fluids to save vital organs. Because of the shock condition (decreased blood pressure), veins collapse and are often impossible to find. IO access may save precious minutes for paramedics and trauma surgeons responsible for their care.
Although the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alternations can be made herein without departing from the spirit and scope of the invention as defined by the following claims.
This application is a continuation of U.S. application Ser. No. 11/380,340, filed Apr. 26, 2006, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/675,246, filed Apr. 27, 2005, and entitled “Vascular Access Kit”, which is a continuation-in-part application of U.S. application Ser. No. 10/449,503 entitled “Apparatus And Method To Provide Emergency Access To Bone Marrow”, filed May 30, 2003 now U.S. Pat. No. 7,670,328, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/384,756, filed May 31, 2002. The entire contents of each of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer. The present disclosure is related to U.S. patent application Ser. No. 10/449,503 filed May 30, 2003; U.S. patent application Ser. No. 10/448,650 filed May 30, 2003; U.S. patent application Ser. No. 10/449,476 filed May 30, 2003; and U.S. patent application Ser. No. 10/987,051 filed Nov. 12, 2004.
Number | Name | Date | Kind |
---|---|---|---|
2317648 | Skiveland | Dec 1899 | A |
2419045 | Wittaker | Dec 1899 | A |
2773501 | Young | Dec 1899 | A |
3104448 | Morrow et al. | Dec 1899 | A |
3120845 | Homer | Dec 1899 | A |
3173417 | Homer | Dec 1899 | A |
3175554 | Stewart | Dec 1899 | A |
3507276 | Burgess et al. | Dec 1899 | A |
3529580 | Stevens | Dec 1899 | A |
3543966 | Ryan et al. | Dec 1899 | A |
3750667 | Pshenichny et al. | Aug 1973 | A |
3815605 | Schmidt et al. | Jun 1974 | A |
3835860 | Garretson | Sep 1974 | A |
3893445 | Hofsess | Jul 1975 | A |
3981398 | Boshoff | Sep 1976 | A |
3991765 | Cohen | Nov 1976 | A |
4021920 | Kirschner et al. | May 1977 | A |
4046254 | Kramer | Sep 1977 | A |
4099518 | Baylis et al. | Jul 1978 | A |
4124026 | Berner et al. | Nov 1978 | A |
4142517 | Stavropoulos et al. | Mar 1979 | A |
4170993 | Alvarez | Oct 1979 | A |
4185619 | Reiss | Jan 1980 | A |
4194505 | Schmitz | Mar 1980 | A |
4258722 | Sessions et al. | Mar 1981 | A |
4262676 | Jamshidi | Apr 1981 | A |
4266555 | Jamshidi | May 1981 | A |
4306570 | Matthews | Dec 1981 | A |
4333459 | Becker | Jun 1982 | A |
4359052 | Staub | Nov 1982 | A |
4381777 | Garnier | May 1983 | A |
4399723 | Marleau | Aug 1983 | A |
4441563 | Walton, II | Apr 1984 | A |
4469109 | Mehl | Sep 1984 | A |
4484577 | Sackner et al. | Nov 1984 | A |
4487209 | Mehl | Dec 1984 | A |
4543966 | Islam et al. | Oct 1985 | A |
4553539 | Morris | Nov 1985 | A |
4578064 | Sarnoff | Mar 1986 | A |
4605011 | Naslund | Aug 1986 | A |
4620539 | Andrews et al. | Nov 1986 | A |
4646731 | Brower | Mar 1987 | A |
4654492 | Koerner et al. | Mar 1987 | A |
4655226 | Lee | Apr 1987 | A |
4659329 | Annis | Apr 1987 | A |
4692073 | Martindell | Sep 1987 | A |
4711636 | Bierman | Dec 1987 | A |
4713061 | Tarello et al. | Dec 1987 | A |
4716901 | Jackson et al. | Jan 1988 | A |
4720881 | Meyers | Jan 1988 | A |
4723945 | Theiling | Feb 1988 | A |
4758225 | Cox et al. | Jul 1988 | A |
4762118 | Lia et al. | Aug 1988 | A |
4772261 | Von Hoff et al. | Sep 1988 | A |
4787893 | Villette | Nov 1988 | A |
4793363 | Ausherman et al. | Dec 1988 | A |
4838282 | Strasser et al. | Jun 1989 | A |
4844259 | Glowczewskie, Jr. et al. | Jul 1989 | A |
4867158 | Sugg | Sep 1989 | A |
4919146 | Rhinehart et al. | Apr 1990 | A |
4921013 | Spalink et al. | May 1990 | A |
4922602 | Mehl | May 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4940459 | Noce | Jul 1990 | A |
4944677 | Alexandre | Jul 1990 | A |
4969870 | Kramer et al. | Nov 1990 | A |
4986279 | O'Neill | Jan 1991 | A |
5002546 | Romano | Mar 1991 | A |
5025797 | Baran | Jun 1991 | A |
5036860 | Leigh et al. | Aug 1991 | A |
5057085 | Kopans | Oct 1991 | A |
5074311 | Hasson | Dec 1991 | A |
5116324 | Brierley et al. | May 1992 | A |
5120312 | Wigness et al. | Jun 1992 | A |
5122114 | Miller et al. | Jun 1992 | A |
5133359 | Kedem | Jul 1992 | A |
5137518 | Mersch | Aug 1992 | A |
5139500 | Schwartz | Aug 1992 | A |
RE34056 | Lindgren et al. | Sep 1992 | E |
5145369 | Lustig et al. | Sep 1992 | A |
5172701 | Leigh et al. | Dec 1992 | A |
5172702 | Leigh et al. | Dec 1992 | A |
5176415 | Choksi | Jan 1993 | A |
5176643 | Kramer et al. | Jan 1993 | A |
5195985 | Hall | Mar 1993 | A |
5203056 | Funk et al. | Apr 1993 | A |
5207697 | Carusillo et al. | May 1993 | A |
5244619 | Burnham | Sep 1993 | A |
5249583 | Mallaby | Oct 1993 | A |
5257632 | Turkel et al. | Nov 1993 | A |
5261877 | Fine et al. | Nov 1993 | A |
5269785 | Bonutti | Dec 1993 | A |
5271414 | Partika et al. | Dec 1993 | A |
5279306 | Mehl | Jan 1994 | A |
5312364 | Jacobs | May 1994 | A |
5312408 | Brown | May 1994 | A |
5315737 | Ouimet | May 1994 | A |
5324300 | Elias et al. | Jun 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5333790 | Christopher | Aug 1994 | A |
5334169 | Brown et al. | Aug 1994 | A |
5341816 | Allen | Aug 1994 | A |
5341823 | Manosalva et al. | Aug 1994 | A |
5348022 | Leigh et al. | Sep 1994 | A |
5356006 | Alpern | Oct 1994 | A |
5357974 | Baldridge | Oct 1994 | A |
5368046 | Scarfone et al. | Nov 1994 | A |
5372583 | Roberts et al. | Dec 1994 | A |
5383859 | Sewell, Jr. | Jan 1995 | A |
5385151 | Scarfone et al. | Jan 1995 | A |
5385553 | Hart et al. | Jan 1995 | A |
5400798 | Baran | Mar 1995 | A |
5405348 | Anspach, Jr. et al. | Apr 1995 | A |
5405362 | Kramer | Apr 1995 | A |
5423824 | Akerfeldt et al. | Jun 1995 | A |
5431655 | Melker et al. | Jul 1995 | A |
5451210 | Kramer | Sep 1995 | A |
5484442 | Melker et al. | Jan 1996 | A |
D369858 | Baker et al. | May 1996 | S |
5514097 | Knauer | May 1996 | A |
5526821 | Jamshidi | Jun 1996 | A |
5529580 | Kusunoki et al. | Jun 1996 | A |
5549565 | Ryan et al. | Aug 1996 | A |
5554154 | Rosenberg | Sep 1996 | A |
5556399 | Huebner | Sep 1996 | A |
5558737 | Brown et al. | Sep 1996 | A |
5571133 | Yoon | Nov 1996 | A |
5586847 | Mattern, Jr. et al. | Dec 1996 | A |
5591188 | Waisman | Jan 1997 | A |
5595186 | Rubinstein et al. | Jan 1997 | A |
5601559 | Melker et al. | Feb 1997 | A |
5632747 | Scarborough et al. | May 1997 | A |
5672155 | Riley et al. | Sep 1997 | A |
5713368 | Leigh | Feb 1998 | A |
5724873 | Hillinger | Mar 1998 | A |
5733262 | Paul | Mar 1998 | A |
5752923 | Terwilliger | May 1998 | A |
5762639 | Gibbs | Jun 1998 | A |
5766221 | Benderev et al. | Jun 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5779708 | Wu | Jul 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5807275 | Jamshidi | Sep 1998 | A |
5807277 | Swaim | Sep 1998 | A |
5810826 | Ånakerfeldt et al. | Sep 1998 | A |
5817052 | Johnson et al. | Oct 1998 | A |
5823970 | Terwilliger | Oct 1998 | A |
D403405 | Terwilliger | Dec 1998 | S |
5858005 | Kriesel | Jan 1999 | A |
5868711 | Kramer et al. | Feb 1999 | A |
5868750 | Schultz | Feb 1999 | A |
5873499 | Leschinsky et al. | Feb 1999 | A |
5873510 | Hirai et al. | Feb 1999 | A |
5885226 | Rubinstein et al. | Mar 1999 | A |
5891085 | Lilley et al. | Apr 1999 | A |
5906797 | Orihara et al. | May 1999 | A |
5911701 | Miller et al. | Jun 1999 | A |
5911708 | Teirstein | Jun 1999 | A |
5916229 | Evans | Jun 1999 | A |
5919172 | Golba, Jr. | Jul 1999 | A |
5921987 | Stone | Jul 1999 | A |
5924864 | Loge et al. | Jul 1999 | A |
5926989 | Oliver, Sr. | Jul 1999 | A |
5927976 | Wu | Jul 1999 | A |
5928238 | Scarborough et al. | Jul 1999 | A |
5941706 | Ura | Aug 1999 | A |
5941851 | Coffey et al. | Aug 1999 | A |
5951026 | Harman, Jr. et al. | Sep 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5980545 | Pacala et al. | Nov 1999 | A |
5993417 | Yerfino et al. | Nov 1999 | A |
5993454 | Longo | Nov 1999 | A |
6007496 | Brannon | Dec 1999 | A |
6017348 | Hart et al. | Jan 2000 | A |
6018094 | Fox | Jan 2000 | A |
6018230 | Casey | Jan 2000 | A |
6022324 | Skinner | Feb 2000 | A |
6027458 | Janssens | Feb 2000 | A |
6033369 | Goldenberg | Mar 2000 | A |
6033411 | Preissman | Mar 2000 | A |
6042585 | Norman | Mar 2000 | A |
6049725 | Emmert et al. | Apr 2000 | A |
6063037 | Mittermeier et al. | May 2000 | A |
6066938 | Hyodo et al. | May 2000 | A |
6071284 | Fox | Jun 2000 | A |
6080115 | Rubinstein | Jun 2000 | A |
6083176 | Terwilliger | Jul 2000 | A |
6086543 | Anderson et al. | Jul 2000 | A |
6086544 | Hibner et al. | Jul 2000 | A |
6096042 | Herbert | Aug 2000 | A |
6102915 | Bresler et al. | Aug 2000 | A |
6106484 | Terwilliger | Aug 2000 | A |
6110128 | Andelin et al. | Aug 2000 | A |
6110129 | Terwilliger | Aug 2000 | A |
6110174 | Nichter | Aug 2000 | A |
6120462 | Hibner et al. | Sep 2000 | A |
6135769 | Kwan | Oct 2000 | A |
6152918 | Padilla et al. | Nov 2000 | A |
6159163 | Strauss et al. | Dec 2000 | A |
6162203 | Haaga | Dec 2000 | A |
6183442 | Athanasiou et al. | Feb 2001 | B1 |
6187768 | Welle et al. | Feb 2001 | B1 |
6210376 | Grayson | Apr 2001 | B1 |
6217561 | Gibbs | Apr 2001 | B1 |
6221029 | Mathis et al. | Apr 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6228088 | Miller et al. | May 2001 | B1 |
6238355 | Daum | May 2001 | B1 |
6247928 | Meller et al. | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6257351 | Ark et al. | Jul 2001 | B1 |
6267763 | Castro | Jul 2001 | B1 |
6273715 | Meller et al. | Aug 2001 | B1 |
6273862 | Privitera et al. | Aug 2001 | B1 |
6283925 | Terwilliger | Sep 2001 | B1 |
6283970 | Lubinus | Sep 2001 | B1 |
6287114 | Meller et al. | Sep 2001 | B1 |
6302852 | Fleming, III et al. | Oct 2001 | B1 |
6309358 | Okubo | Oct 2001 | B1 |
6312394 | Fleming, III | Nov 2001 | B1 |
6315737 | Skinner | Nov 2001 | B1 |
6325806 | Fox | Dec 2001 | B1 |
6328701 | Terwilliger | Dec 2001 | B1 |
6328744 | Harari et al. | Dec 2001 | B1 |
6358252 | Shapira | Mar 2002 | B1 |
6382212 | Borchard | May 2002 | B1 |
6402701 | Kaplan et al. | Jun 2002 | B1 |
6419490 | Kitchings Weathers, Jr. | Jul 2002 | B1 |
6425888 | Embleton et al. | Jul 2002 | B1 |
6428487 | Burdorff et al. | Aug 2002 | B1 |
6443910 | Krueger et al. | Sep 2002 | B1 |
6458117 | Pollins, Sr. | Oct 2002 | B1 |
6468248 | Gibbs | Oct 2002 | B1 |
6478751 | Krueger et al. | Nov 2002 | B1 |
6488636 | Bryan et al. | Dec 2002 | B2 |
6523698 | Dennehey et al. | Feb 2003 | B1 |
6527736 | Attinger et al. | Mar 2003 | B1 |
6527778 | Athanasiou et al. | Mar 2003 | B2 |
6540694 | Van Bladel et al. | Apr 2003 | B1 |
6547511 | Adams | Apr 2003 | B1 |
6547561 | Meller et al. | Apr 2003 | B2 |
6550786 | Gifford et al. | Apr 2003 | B2 |
6554779 | Viola et al. | Apr 2003 | B2 |
6555212 | Boiocchi et al. | Apr 2003 | B2 |
6572563 | Ouchi | Jun 2003 | B2 |
6575919 | Reiley et al. | Jun 2003 | B1 |
6582399 | Smith et al. | Jun 2003 | B1 |
6585622 | Shum et al. | Jul 2003 | B1 |
6595362 | Penney et al. | Jul 2003 | B2 |
6595911 | LoVuolo | Jul 2003 | B2 |
6595979 | Epstein et al. | Jul 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6616632 | Sharp et al. | Sep 2003 | B2 |
6620111 | Stephens et al. | Sep 2003 | B2 |
6626173 | Genova et al. | Sep 2003 | B2 |
6626848 | Neuenfeldt | Sep 2003 | B2 |
6626887 | Wu | Sep 2003 | B1 |
6638235 | Miller et al. | Oct 2003 | B2 |
6656133 | Voegele et al. | Dec 2003 | B2 |
6689072 | Kaplan et al. | Feb 2004 | B2 |
6690308 | Hayami | Feb 2004 | B2 |
6702760 | Krause et al. | Mar 2004 | B2 |
6702761 | Damadian et al. | Mar 2004 | B1 |
6706016 | Cory et al. | Mar 2004 | B2 |
6716192 | Orosz, Jr. | Apr 2004 | B1 |
6716215 | David et al. | Apr 2004 | B1 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6730043 | Krueger et al. | May 2004 | B2 |
6730044 | Stephens et al. | May 2004 | B2 |
6749576 | Bauer | Jun 2004 | B2 |
6752768 | Burdorff et al. | Jun 2004 | B2 |
6752816 | Culp et al. | Jun 2004 | B2 |
6758824 | Miller et al. | Jul 2004 | B1 |
6761726 | Findlay et al. | Jul 2004 | B1 |
6796957 | Carpenter et al. | Sep 2004 | B2 |
6846314 | Shapira | Jan 2005 | B2 |
6849051 | Sramek et al. | Feb 2005 | B2 |
6855148 | Foley et al. | Feb 2005 | B2 |
6860860 | Viola | Mar 2005 | B2 |
6875183 | Cervi | Apr 2005 | B2 |
6875219 | Arramon et al. | Apr 2005 | B2 |
6884245 | Spranza, III | Apr 2005 | B2 |
6887209 | Kadziauskas et al. | May 2005 | B2 |
6890308 | Islam | May 2005 | B2 |
6896141 | McMichael et al. | May 2005 | B2 |
6905486 | Gibbs | Jun 2005 | B2 |
6930461 | Rutkowski | Aug 2005 | B2 |
6942669 | Kurc | Sep 2005 | B2 |
6969373 | Schwartz et al. | Nov 2005 | B2 |
7001342 | Faciszewski | Feb 2006 | B2 |
7008381 | Janssens | Mar 2006 | B2 |
7008383 | Damadian et al. | Mar 2006 | B1 |
7008394 | Geise et al. | Mar 2006 | B2 |
7018343 | Plishka | Mar 2006 | B2 |
7025732 | Thompson et al. | Apr 2006 | B2 |
7063672 | Schramm | Jun 2006 | B2 |
7063703 | Reo | Jun 2006 | B2 |
7137985 | Jahng | Nov 2006 | B2 |
7186257 | Kim | Mar 2007 | B2 |
7207949 | Miles et al. | Apr 2007 | B2 |
7226450 | Athanasiou et al. | Jun 2007 | B2 |
7229401 | Kindlein | Jun 2007 | B2 |
7278972 | Lamoureux et al. | Oct 2007 | B2 |
7331462 | Steppe | Feb 2008 | B2 |
7331930 | Faciszewski | Feb 2008 | B2 |
7513722 | Greenberg et al. | Apr 2009 | B2 |
7615043 | Zhou | Nov 2009 | B2 |
7670328 | Miller | Mar 2010 | B2 |
7699850 | Miller | Apr 2010 | B2 |
7811260 | Miller et al. | Oct 2010 | B2 |
7815642 | Miller | Oct 2010 | B2 |
7850620 | Miller et al. | Dec 2010 | B2 |
7951089 | Miller | May 2011 | B2 |
7988643 | Hoffmann et al. | Aug 2011 | B2 |
8038664 | Miller et al. | Oct 2011 | B2 |
8217561 | Fukuzawa et al. | Jul 2012 | B2 |
8419683 | Miller et al. | Apr 2013 | B2 |
8480632 | Miller et al. | Jul 2013 | B2 |
8506568 | Miller | Aug 2013 | B2 |
8641715 | Miller | Feb 2014 | B2 |
8656929 | Miller et al. | Feb 2014 | B2 |
8668698 | Miller et al. | Mar 2014 | B2 |
8684978 | Miller et al. | Apr 2014 | B2 |
8690791 | Miller | Apr 2014 | B2 |
8715287 | Miller | May 2014 | B2 |
20010005778 | Ouchi | Jun 2001 | A1 |
20010014439 | Meller et al. | Aug 2001 | A1 |
20010047183 | Privitera et al. | Nov 2001 | A1 |
20010053888 | Athanasiou et al. | Dec 2001 | A1 |
20020042581 | Cervi | Apr 2002 | A1 |
20020055713 | Gibbs | May 2002 | A1 |
20020120212 | Ritchart et al. | Aug 2002 | A1 |
20020138021 | Pflueger | Sep 2002 | A1 |
20030028146 | Aves | Feb 2003 | A1 |
20030032939 | Gibbs | Feb 2003 | A1 |
20030036747 | Ie et al. | Feb 2003 | A1 |
20030050574 | Krueger | Mar 2003 | A1 |
20030114858 | Athanasiou et al. | Jun 2003 | A1 |
20030125639 | Fisher et al. | Jul 2003 | A1 |
20030153842 | Lamoureux et al. | Aug 2003 | A1 |
20030191414 | Reiley et al. | Oct 2003 | A1 |
20030195436 | Van Bladel et al. | Oct 2003 | A1 |
20030195524 | Banner | Oct 2003 | A1 |
20030199787 | Schwindt | Oct 2003 | A1 |
20030216667 | Viola | Nov 2003 | A1 |
20030225344 | Miller | Dec 2003 | A1 |
20030225364 | Kraft et al. | Dec 2003 | A1 |
20030225411 | Miller | Dec 2003 | A1 |
20040019297 | Angel | Jan 2004 | A1 |
20040019299 | Ritchart et al. | Jan 2004 | A1 |
20040034280 | Privitera et al. | Feb 2004 | A1 |
20040049128 | Miller et al. | Mar 2004 | A1 |
20040064136 | Papineau et al. | Apr 2004 | A1 |
20040073139 | Hirsch et al. | Apr 2004 | A1 |
20040092946 | Bagga et al. | May 2004 | A1 |
20040127814 | Negroni | Jul 2004 | A1 |
20040153003 | Cicenas et al. | Aug 2004 | A1 |
20040158172 | Hancock | Aug 2004 | A1 |
20040158173 | Voegele et al. | Aug 2004 | A1 |
20040162505 | Kaplan et al. | Aug 2004 | A1 |
20040191897 | Muschler | Sep 2004 | A1 |
20040210161 | Burdorff et al. | Oct 2004 | A1 |
20040210198 | Shih | Oct 2004 | A1 |
20040215102 | Ikehara et al. | Oct 2004 | A1 |
20040220497 | Findlay et al. | Nov 2004 | A1 |
20050027210 | Miller | Feb 2005 | A1 |
20050040060 | Andersen et al. | Feb 2005 | A1 |
20050075581 | Schwindt | Apr 2005 | A1 |
20050085838 | Thompson et al. | Apr 2005 | A1 |
20050101880 | Cicenas et al. | May 2005 | A1 |
20050113716 | Mueller, Jr. et al. | May 2005 | A1 |
20050119660 | Bourlion et al. | Jun 2005 | A1 |
20050124915 | Eggers et al. | Jun 2005 | A1 |
20050131345 | Miller | Jun 2005 | A1 |
20050148940 | Miller | Jul 2005 | A1 |
20050165328 | Heske et al. | Jul 2005 | A1 |
20050165403 | Miller | Jul 2005 | A1 |
20050165404 | Miller | Jul 2005 | A1 |
20050171504 | Miller | Aug 2005 | A1 |
20050182394 | Spero et al. | Aug 2005 | A1 |
20050200087 | Vasudeva et al. | Sep 2005 | A1 |
20050203439 | Heske et al. | Sep 2005 | A1 |
20050209530 | Pflueger | Sep 2005 | A1 |
20050215921 | Hibner et al. | Sep 2005 | A1 |
20050228309 | Fisher et al. | Oct 2005 | A1 |
20050236940 | Rockoff | Oct 2005 | A1 |
20050261693 | Miller et al. | Nov 2005 | A1 |
20060011506 | Riley | Jan 2006 | A1 |
20060015066 | Turieo et al. | Jan 2006 | A1 |
20060036212 | Miller | Feb 2006 | A1 |
20060052790 | Miller | Mar 2006 | A1 |
20060074345 | Hibner | Apr 2006 | A1 |
20060079774 | Anderson | Apr 2006 | A1 |
20060089565 | Schramm | Apr 2006 | A1 |
20060122535 | Daum | Jun 2006 | A1 |
20060129082 | Rozga | Jun 2006 | A1 |
20060144548 | Beckman et al. | Jul 2006 | A1 |
20060149163 | Hibner et al. | Jul 2006 | A1 |
20060167377 | Ritchart et al. | Jul 2006 | A1 |
20060167378 | Miller | Jul 2006 | A1 |
20060167379 | Miller | Jul 2006 | A1 |
20060184063 | Miller | Aug 2006 | A1 |
20060189940 | Kirsch | Aug 2006 | A1 |
20060206132 | Conquergood et al. | Sep 2006 | A1 |
20070016100 | Miller | Jan 2007 | A1 |
20070049945 | Miller | Mar 2007 | A1 |
20070149920 | Michels et al. | Jun 2007 | A1 |
20070213735 | Saadat et al. | Sep 2007 | A1 |
20070270775 | Miller et al. | Nov 2007 | A1 |
20080015467 | Miller | Jan 2008 | A1 |
20080015468 | Miller | Jan 2008 | A1 |
20080045857 | Miller et al. | Feb 2008 | A1 |
20080045860 | Miller et al. | Feb 2008 | A1 |
20080045861 | Miller et al. | Feb 2008 | A1 |
20080045965 | Miller et al. | Feb 2008 | A1 |
20080140014 | Miller et al. | Jun 2008 | A1 |
20080177200 | Ikehara et al. | Jul 2008 | A1 |
20080215056 | Miller et al. | Sep 2008 | A1 |
20080221580 | Miller et al. | Sep 2008 | A1 |
20090069716 | Freeman et al. | Mar 2009 | A1 |
20090093677 | Smith | Apr 2009 | A1 |
20090194446 | Miller et al. | Aug 2009 | A1 |
20100204611 | Zambelli | Aug 2010 | A1 |
20110046507 | Herndon | Feb 2011 | A1 |
20110082387 | Miller et al. | Apr 2011 | A1 |
20110306841 | Lozman et al. | Dec 2011 | A1 |
20120165832 | Oostman, Jr. et al. | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
2138842 | Jun 1996 | CA |
2454600 | Feb 2003 | CA |
2664675 | Dec 2004 | CN |
2320209 | May 2009 | CN |
10057931 | Nov 2000 | DE |
0517000 | Dec 1992 | EP |
0807412 | Nov 1997 | EP |
1099450 | May 2001 | EP |
1314452 | May 2003 | EP |
1421907 | May 2004 | EP |
1447050 | Aug 2004 | EP |
853349 | Mar 1940 | FR |
2457105 | May 1979 | FR |
2516386 | Nov 1981 | FR |
2130890 | Jun 1984 | GB |
59119808 | Aug 1984 | JP |
6132663 | Sep 1986 | JP |
1052433 | Feb 1989 | JP |
2001505076 | Apr 2001 | JP |
9208410 | May 1992 | WO |
9307819 | Apr 1993 | WO |
9631164 | Oct 1996 | WO |
9806337 | Feb 1998 | WO |
9852638 | Nov 1998 | WO |
9918866 | Apr 1999 | WO |
9952444 | Oct 1999 | WO |
0009024 | Feb 2000 | WO |
00056220 | Sep 2000 | WO |
0178590 | Oct 2001 | WO |
0241792 | May 2002 | WO |
02096497 | Dec 2002 | WO |
2003015637 | Feb 2003 | WO |
2005072625 | Aug 2005 | WO |
05110259 | Nov 2005 | WO |
2005112800 | Dec 2005 | WO |
2008033874 | Mar 2008 | WO |
08081438 | Jul 2008 | WO |
2011123703 | Oct 2011 | WO |
Entry |
---|
International PCT Search Report PCT/US03/17167, 8 pages, dated Sep. 16, 2003. |
International PCT Search Report PCT/US03/17203, 8 pages, dated Sep. 16, 2003. |
International PCT Search Report PCT/US2004/037753, 6 pages, dated Apr. 19, 2005. |
International PCT Search Report and Written Opinion PCT/US2004/037753, 16 pages, dated Jul. 8, 2005. |
Cummins, Richard O., et al, “ACLS—Principles and Practice”, ACLS—The Reference Textbook, American Heart Association, No. 214-218, 2003. |
International Preliminary Report on Patentability PCT/US2005/002484, 9 pages, dated Aug. 3, 2006. |
Communication relating to the results of the partial International Search Report for PCT/US2005/002484, 6 pages, dated May 19, 2005. |
Riley et al., “A Pathologist's Perspective on Bone Marrow Aspiration Biopsy: I. Performing a Bone Marrow Examination,” Journal of Clinical Laboratory Analysis 18, pp. 70-90, 2004. |
Official Action for European Application No. 03756317.8 (4 pages), dated Dec. 28, 2006. |
International Search Report and Written Opinion for International Application No. PCT/US2006/025201 (18 pages), dated Jan. 29, 2007. |
Pediatrics, “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care of Pediatric and Neonatal Patients: Pediatric Advanced Life Support,” www.pediatrics.org, Official Journal of the American Academy of Pediatrics (26 pages), Jan. 21, 2007. |
Australian Exam Report on Patent Application No. 2003240970, 2 pages, dated Oct. 15, 2007. |
“Proven reliability for quality bone marrow samples”, Special Procedures, Cardinal Health, 6 pages, 2003. |
Liakat A. Parapia, Trepanning or trephines: a history of bone marrow biopsy, British Journal of Haematoloay, pp. 14-19, 2007. |
Astrom, “Automatic Biopsy Instruments Used Through a Coaxial Bone Biopsy System with an Eccentric Drill Tip,” Acta Radiologica 36: 237-242. May 1995. |
Astrom, “CT-guided Transstemal Core Biopsy of Anterior Mediastinal Masses,” Radiology 199:564-567. May 1996. |
BioAccess.com, Single Use Small Bone Power Tool—How It Works. Accessed Jun. 9, 2008. |
Buckley et al., “CT-guided bone biopsy: initial experience with commercially available hand held Black and Decker drill,” European Journal of Radiology 61: 176-180. 2007. |
F.A.S.T. 1 Intraosseous Infusion System with Depth-Control Mechanism Brochure. 2000. |
Gunal et al., “Compartment Syndrome After Intraosseous Infusion: An Experimental Study in Dogs,” J of Pediatric SurRery 31(11): 1491-1493. Nov. 1996. |
Hakan et al., “CT-guided bone biopsy performed by means of coaxial biopsy system with an eccentric drill,” Radiology 549-552. Aug. 1993. |
Notice of Allowance in U.S. Appl. No. 11/042,912, dated Sep. 24, 2013. |
Notice of Allowance in U.S. Appl. No. 11/619,390 dated Jul. 3, 2014. |
Notice of Allowance in U.S. Appl. No. 11/620,927 dated Jun. 3, 2014. |
Notice of Allowance in U.S. Appl. No. 11/853,678 dated Jul. 11, 2013. |
Notice of Allowance in U.S. Appl. No. 11/853,678, dated Oct. 11, 2011. |
Notice of Allowance in U.S. Appl. No. 11/853,678, dated Nov. 8, 2013. |
Notice of Allowance in U.S. Appl. No. 12/331,979, dated Dec. 23, 2013. |
Notice of Allowance in U.S. Appl. No. 12/407,651 dated Jun. 11, 2014. |
Notice of Allowance in U.S. Appl. No. 12/427,310, dated Nov. 29, 2013. |
Notice of Allowance in U.S. Appl. No. 12/899,696 dated Jul. 18, 2013. |
Notice of Allowance in U.S. Appl. No. 12/899,696, dated Nov. 12, 2013. |
Notice of Allowance in U.S. Appl. No. 14/721,144 dated Jul. 22, 2014. |
Notice of Allowance issued in U.S. Appl. No. 11/253,467, dated Mar. 29, 2011. |
Notice of Allowance issued in U.S. Appl. No. 11/253,959, dated May 20, 2013. |
Notice of Allowance dated on Mar. 4, 2014 in U.S. Appl. No. 11/253,467. |
Office Action for U.S. Appl. No. 11/042,912, dated Mar. 19, 2010. |
Office Action for U.S. Appl. No. 11/253,467, dated Apr. 28, 2011. |
Office Action for U.S. Appl. No. 11/253,467, dated Jul. 22, 2010. |
Office Action for U.S. Appl. No. 11/253,959, dated Mar. 30, 2011. |
Office Action for U.S. Appl. No. 12/905,659, dated Mar. 21, 2011. |
Office Action for U.S. Appl. No. 12/905,659, dated May 13, 2011. |
Pediatric Emergency, Intraosseous Infusion for Administration of Fluids and Drugs, www.cookgroup.com, 1pg, 2000. |
Pediatrics, Official Journal of the American Academy of Pediatrics, “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care of Pediatric and Neonatal Patients: Pediatric Advanced Life Support”, Downloaded from www.pediatrics.org, Feb. 21, 2007. |
U.S. Appl. No. 11/427,501 Non-Final Office Action, 14 pages, dated Aug. 7, 2008. |
Vidacare Corporation Comments to Intraosseous Vascular Access Position Paper, Infusion Nurses Society, 6 pages, May 4, 2009. |
Number | Date | Country | |
---|---|---|---|
20160066954 A1 | Mar 2016 | US |
Number | Date | Country | |
---|---|---|---|
60675246 | Apr 2005 | US | |
60384756 | May 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11380340 | Apr 2006 | US |
Child | 14791654 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10449503 | May 2003 | US |
Child | 11380340 | US |